Product Center
Received the clinical approval for a new drug of the first class of biological products
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-11-11
- Views:
(Summary description)In 2017, the company used its own patented technology to develop a new class of biological products: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA for clinical appro
Received the clinical approval for a new drug of the first class of biological products
(Summary description)In 2017, the company used its own patented technology to develop a new class of biological products: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA for clinical appro
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-11-11 10:57
- Views:
In 2017, the company used its own patented technology to develop a new class of biological products: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA for clinical approval.
Relevant information
-
Ab&B Bio Tech CO., LTD. JS invited to attend the China Ukraine Trade Cooperation SeminarDuring the visit, the China Uruguay Trade Cooperation Seminar, organized by the China Council for the Promotion of International Trade, was grandly held in Beijing on the 21st. Uruguayan President Lac - The kickoff meeting for the Phase I clinical trial of freeze-dried human rabies vaccine (human diploid cells) was successfully held 11-27
- Successfully selected as a national open topic! 11-15
- Ab&B Bio-Tech CO.,LTD.JS The delegation went to Brazil, Uruguay, Chile, and Spain to carry out multinational exchange and cooperation activities 11-06
- The launch ceremony of the four valent influenza virus subunit vaccine Huierkangxin was successfully held! 09-26
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
